Hypogonadism in the HIV-Infected Man

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 3, 2014, Pages 709-730

  Rochira, Vincenzo ^a,b   Guaraldi, Giovanni ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

Author keywords

Androgen deficiency; Antiretroviral therapy; Gonadotropins; Health status; LH; Premature aging; SHBG; Testosterone

Indexed keywords

ANTIRETROVIRUS AGENT; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BIOCHEMISTRY; DRUG FORMULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; BLOOD; COMPLICATION; HIV INFECTIONS; HORMONE SUBSTITUTION; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; RISK FACTORS; TESTOSTERONE;

EID: 84907372170     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2014.06.005     Document Type: Review

References (90)

1. Lefrere J.J., Laplanche J.L., Vittecoq D., et al. Hypogonadism in AIDS. AIDS 1988, 2(2):135-136.
2. Dobs A.S., Dempsey M.A., Ladenson P.W., et al. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988, 84(3):611-616.
3. Sellmeyer D.E., Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996, 17(5):518-532.
4. Grinspoon S., Corcoran C., Askari H., et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 129(1):18-26.
5. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. NEngl J Med 1998, 338(13):853-860.
6. Available at: Accessed May 5, 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.
7. Croxson T.S., Chapman W.E., Miller L.K., et al. Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men. JClin Endocrinol Metab 1989, 68(2):317-321.
8. Villette J.M., Bourin P., Doinel C., et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. JClin Endocrinol Metab 1990, 70(3):572-577.
9. Raffi F., Brisseau J.M., Planchon B., et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991, 5(6):729-733.
10. Wagner G., Rabkin J.G., Rabkin R. Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness. JAcquir Immune Defic Syndr Hum Retrovirol 1995, 8(2):204-207.
11. Grinspoon S., Corcoran C., Lee K., et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. JClin Endocrinol Metab 1996, 81(11):4051-4058.
12. Salehian B., Jacobson D., Swerdloff R.S., et al. Testicular pathologic changes and the pituitary-testicular axis during human immunodeficiency virus infection. Endocr Pract 1999, 5(1):1-9.
13. Arver S., Sinha-Hikim I., Beall G., et al. Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. JAndrol 1999, 20(5):611-618.
14. Laudat A., Blum L., Guéchot J., et al. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol 1995, 133(4):418-424.
15. Merenich J.A., McDermott M.T., Asp A.A., et al. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. JClin Endocrinol Metab 1990, 70(3):566-571.
16. Dobs A.S., Few W.L., Blackman M.R., et al. Serum hormones in men with human immunodeficiency virus-associated wasting. JClin Endocrinol Metab 1996, 81(11):4108-4112.
17. Rosner W., Auchus R.J., Azziz R., et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. JClin Endocrinol Metab 2007, 92(2):405-413.
18. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. JClin Endocrinol Metab 2010, 95(6):2536-2559.
19. Berger D, Muurahainen N, Wittert H, etal. Hypogonadism and wasting in the era of HAART in HIV-infected patients. Proceedings of 12th International AIDS Conference. [abstract: 32174]. Geneva (Switzerland), June 28 - July 3, 1998.
20. Rietschel P., Corcoran C., Stanley T., et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000, 31(5):1240-1244.
21. Fisher A, Desyatnik M, Baaj A. The prevalence of hypogonadism in HIV infected patients receiving HAART. XIII International AIDS Conference. [abstract: TuPeB3180]. Durban (South Africa), July 9-14, 2000.
22. Crum-Cianflone N.F., Bavaro M., Hale B., et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 2007, 21(1):9-19.
23. Moreno-Pérez O., Escoin C., Serna-Candel C., et al. The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected males. JSex Med 2010, 7(8):2873-2883.
24. Rochira V., Zirilli L., Orlando G., et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One 2011, 6(12):e28512.
25. Pepe J., Isidori A.M., Falciano M., et al. The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol (Oxf) 2012, 77(5):672-678.
26. Monroe A.K., Dobs A.S., Cofrancesco J., et al. Testosterone and Abnormal Glucose Metabolism in an Inner-City Cohort. JMens Health 2012, 9(3).
27. Sunchatawirul K., Tantiwongse K., Chathaisong P., et al. Hypogonadism among HIV-infected men in Thailand. Int J STD AIDS 2012, 23(12):876-881.
28. De Ryck I., Van Laeken D., Apers L., et al. Erectile dysfunction, testosterone deficiency, and risk of coronary heart disease in a cohort of men living with HIV in Belgium. JSex Med 2013, 10(7):1816-1822.
29. Blick G. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Postgrad Med 2013, 125(2):30-39.
30. Monroe A.K., Dobs A.S., Palella F.J., et al. Morning free and total testosterone in HIV-infected men: implications for the assessment of hypogonadism. AIDS Res Ther 2014, 11(1):6.
31. Dubé M.P., Parker R.A., Mulligan K., et al. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis 2007, 45(1):120-126.
32. Collazos J., Esteban M. Has prolactin a role in the hypogonadal status of HIV-infected patients?. JInt Assoc Physicians AIDS Care 2009, 8(1):43-46.
33. Klein R.S., Lo Y., Santoro N., et al. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005, 41(12):1794-1803.
34. Wunder D.M., Fux C.A., Bersinger N.A., et al. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV Med 2008, 9(6):427-432.
35. Amini Lari M., Parsa N., Marzban M., et al. Depression, testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV infection. AIDS Behav 2012, 16(8):2236-2243.
36. Araujo A.B., O'Donnell A.B., Brambilla D.J., et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. JClin Endocrinol Metab 2004, 89(12):5920-5926.
37. Schneider H.J., Sievers C., Klotsche J., et al. Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study. Clin Endocrinol 2009, 70(3):446-454.
38. Tajar A., Forti G., O'Neill T.W., et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. JClin Endocrinol Metab 2010, 95(4):1810-1818.
39. Kaufman J.M., Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab 1997, 11(2):289-309.
40. Lo J.C., Schambelan M. Reproductive function in human immunodeficiency virus infection. JClin Endocrinol Metab 2001, 86(6):2338-2343.
41. Monroe A.K., Dobs A.S., Xu X., et al. Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. JAcquir Immune Defic Syndr 2011, 58(2):173-180.
42. Monroe A.K., Dobs A.S., Xu X., et al. Low free testosterone in HIV-infected men is not associated with subclinical cardiovascular disease. HIV Med 2012, 13(6):358-366.
43. Ashby J., Goldmeier D., Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol 2014, 55(1):9-16.
44. Mylonakis E., Koutkia P., Grinspoon S. Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women. Clin Infect Dis 2001, 33(6):857-864.
45. Zirilli L., Orlando G., Carli F., et al. GH response to GHRH plus arginine is impaired in lipoatrophic women with human immunodeficiency virus compared with controls. Eur J Endocrinol 2012, 166(3):415-424.
46. Brigante G., Diazzi C., Ansaloni A., et al. Gender differences in GH response to GHRH+ARG in lipodystrophic patients with HIV: a key role for body fat distribution. Eur J Endocrinol 2014, 170(5):685-696.
47. Zirilli L., Orlando G., Diazzi C., et al. Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?. JEndocrinol Invest 2008, 31(Suppl 9):33-38.
48. Sano T., Kovacs K., Scheithauer B.W., et al. Pituitary pathology in acquired immunodeficiency syndrome. Arch Pathol Lab Med 1989, 113(9):1066-1070.
49. Poretsky L., Can S., Zumoff B. Testicular dysfunction in human immunodeficiency virus-infected men. Metabolism 1995, 44(7):946-953.
50. Buvat J., Maggi M., Guay A., et al. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. JSex Med 2013, 10(1):245-284.
51. Rochira V., Zirilli L., Genazzani A.D., et al. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback. Eur J Endocrinol 2006, 155(4):513-522.
52. Woolf P.D., Hamill R.W., McDonald J.V., et al. Transient hypogonadotropic hypogonadism caused by critical illness. JClin Endocrinol Metab 1985, 60(3):444-450.
53. Morley J.E., Melmed S. Gonadal dysfunction in systemic disorders. Metabolism 1979, 28(10):1051-1073.
54. Travison T.G., Araujo A.B., Kupelian V., et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. JClin Endocrinol Metab 2007, 92(2):549-555.
55. Wu F.C., Tajar A., Beynon J.M., et al. Identification of late-onset hypogonadism in middle-aged and elderly men. NEngl J Med 2010, 363(2):123-135.
56. Corona G, Rastrelli G, Maseroli E, et-al. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology, in press. http://dx.doi.org/10.1111/j.2047-2927.2014.00241.x.
57. Miller K.K. Endocrine effects of anorexia nervosa. Endocrinol Metab Clin North Am 2013, 42(3):515-528.
58. Warner M.H., Beckett G.J. Mechanisms behind the non-thyroidal illness syndrome: an update. JEndocrinol 2010, 205(1):1-13.
59. Handelsman D.J. An old emperor finds new clothing: rejuvenation in our time. Asian J Androl 2011, 13(1):125-129.
60. Deeks S.G., Phillips A.N. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009, 338:a3172.
61. Guaraldi G., Prakash M., Moecklinghoff C., et al. Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. AIDS Rev 2014, 16(2):75-89. 10.1093/infdis/jiu258.
62. De Paepe M.E., Vuletin J.C., Lee M.H., et al. Testicular atrophy in homosexual AIDS patients: an immune-mediated phenomenon?. Hum Pathol 1989, 20(6):572-578.
63. Azu O.O. Highly active antiretroviral therapy (HAART) and testicular morphology: current status and a case for a stereologic approach. JAndrol 2012, 33(6):1130-1142.
64. Roulet V., Satie A.P., Ruffault A., et al. Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and invitro. Am J Pathol 2006, 169(6):2094-2103.
65. Wang C., Nieschlag E., Swerdloff R., et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. JAndrol 2009, 30(1):1-9.
66. Travison T.G., Morley J.E., Araujo A.B., et al. The relationship between libido and testosterone levels in aging men. JClin Endocrinol Metab 2006, 91(7):2509-2513.
67. Hall S.A., Esche G.R., Araujo A.B., et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. JClin Endocrinol Metab 2008, 93(10):3870-3877.
68. Zitzmann M., Faber S., Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. JClin Endocrinol Metab 2006, 91(11):4335-4343.
69. Powderly W.G. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep 2012, 9(3):218-222.
70. Santi D., Brigante G., Zona S., et al. Male sexual dysfunction and HIV-a clinical perspective. Nat Rev Urol 2014, 11(2):99-109.
71. Guaraldi G., Luzi K., Murri R., et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antivir Ther 2007, 12(7):1059-1065.
72. Granata A.R., Rochira V., Lerchl A., et al. Relationship between sleep-related erections and testosterone levels in men. JAndrol 1997, 18(5):522-527.
73. Rochira V., Zirilli L., Madeo B., et al. Sex steroids and sexual desire mechanism. JEndocrinol Invest 2003, 26(Suppl 3):29-36.
74. Sartorius G.A., Handelsman D.J. Testicular dysfunction in systemic diseases. Andrology male reproductive health and dysfunction 2010, 339-364. Springer-Verlag, Berlin (Germany). 3rd edition. E. Nieschlag, H.M. Behre, S. Nieschlag (Eds.).
75. Claramonte M., García-Cruz E., Luque P., et al. Prevalence and risk factors of erectile dysfunction and testosterone deficiency symptoms in a rural population in Uganda. Arch Esp Urol 2012, 65(7):689-697.
76. Petak S.M., Nankin H.R., Spark R.F., American Association of Clinical Endocrinologists, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002, 8(6):440-456.
77. EACS guidelines version 7.0. 2013. Available at: Accessed May 5, 2014. http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf.
78. Aberg J.A., Gallant J.E., Ghanem K.G., et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014, 58(1):1-10.
79. Monroe A.K., Brown T.T. Free testosterone for hypogonadism assessment in HIV-infected men. Clin Infect Dis 2014, 58(11):1640.
80. Giagulli V.A., Kaufman J.M., Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. JClin Endocrinol Metab 1994, 79(4):997-1000.
81. Martin M.E., Benassayag C., Amiel C., et al. Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+ patients. JEndocrinol Invest 1992, 15(8):597-603.
82. Phongtankuel V., Schrank G., Campbell E.N., et al. Elevated testosterone levels in HIV-infected men: case report and a retrospective chart review. JInt Assoc Provid AIDS Care 2013, 12(5):315-318.
83. Wasserman P., Segal-Maurer S., Rubin D. Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone. JSex Med 2008, 5(1):241-247.
84. Hua X., Sun Y., Zhong Y., et al. Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Clin Endocrinol (Oxf) 2014, 80(6):877-883.
85. Nguyen H.V., Mollison L.C., Taylor T.W., et al. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern Med J 2006, 36(6):362-366.
86. Bhasin S., Storer T.W., Javanbakht M., et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000, 283(6):763-770.
87. Corona G., Rastrelli G., Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013, 27(4):557-579.
88. Knapp P.E., Storer T.W., Herbst K.L., et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 2008, 294(6):E1135-E1143.
89. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. NEngl J Med 2010, 363(2):109-122.
90. Vigen R., O'Donnell C.I., Barón A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013, 310(17):1829-1836.